Chugai ( Chugai )

Chugai

Chugai's picture

About Chugai

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

Chugai press release, blog etc

11/15/2018 - 22:40 Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in the U.S.
10/18/2018 - 16:53 Guidelines on Relation with Medical Institutions and Patient Groups
10/15/2018 - 14:05 Message from the Deputy Chairman of the Board
10/15/2018 - 13:42 Chugai Expresses its Support for the Japan Climate Action Summit Declaration
10/12/2018 - 09:12 Filing of Lawsuit on Patent Infringement Concerning Herceptin Injection, and a Petition for Provisional Disposition Order (1)
10/12/2018 - 08:23 Filing of Lawsuit on Patent Infringement Concerning Herceptin Injection, and a Petition for Provisional Disposition Order (2)
10/12/2018 - 08:19 Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
10/01/2018 - 05:56 Chugai Redesigns Corporate Website
09/27/2018 - 06:31 Chugai Sponsors 2018 Wheelchair Softball Tournament in Tokyo
09/27/2018 - 05:40 Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833
09/20/2018 - 04:29 Announcement Regarding the Order to Dismiss in a Lawsuit against Chugai in the U.S.
09/14/2018 - 05:21 Chugai Selected for the Fourth Time for Dow Jones Sustainability Asia Pacific Index
08/30/2018 - 13:34 Results of Global Phase III Study with Chugai's HEMLIBRA for Hemophilia A without Inhibitors Published in the New England Journal of Medicine
08/29/2018 - 12:36 Chugai Obtains Platinum Kurumin Certification from the Minister of Health, Labour and Welfare as a Company Supporting Childrearing
08/29/2018 - 12:30 Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody "GAZYVA "
08/03/2018 - 05:48 Application for Approval of Additional Indication of
08/02/2018 - 19:02 Anti-CD20 Monoclonal Antibody RITUXAN , Application for Approval of Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
07/26/2018 - 11:02 Chugai Pharmabody Research Pte. Ltd., Chugais Research Subsidiary